{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.8","upperLimit":"4.2","value":"2.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"72"}],"units":"Participants"}],"description":"Time to response (TTR) was defined as the interval from the start of idelalisib treatment to the first documentation of CR or PR (or MR for participants with WM) as assessed by the study IRC.","dispersionType":"Inter-Quartile Range","groups":[{"description":"Idelalisib 150 mg tablet administered orally twice daily until tumor progression or development of unacceptable toxicity.","id":"OG000","title":"Idelalisib"}],"paramType":"MEDIAN","populationDescription":"Participants in the ITT Analysis Set who achieved a CR or PR (or MR for participants with WM) were analyzed.","reportingStatus":"POSTED","timeFrame":"Start of Treatment to End of Treatment (up to 81 months)","title":"Time to Response","type":"SECONDARY","unitOfMeasure":"months"}